almotriptan has been researched along with 1-methyl-d-lysergic acid butanolamide in 2 studies
| Studies (almotriptan) | Trials (almotriptan) | Recent Studies (post-2010) (almotriptan) | Studies (1-methyl-d-lysergic acid butanolamide) | Trials (1-methyl-d-lysergic acid butanolamide) | Recent Studies (post-2010) (1-methyl-d-lysergic acid butanolamide) |
|---|---|---|---|---|---|
| 188 | 59 | 42 | 29 | 0 | 9 |
| Protein | Taxonomy | almotriptan (IC50) | 1-methyl-d-lysergic acid butanolamide (IC50) |
|---|---|---|---|
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.912 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for almotriptan and 1-methyl-d-lysergic acid butanolamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for almotriptan and 1-methyl-d-lysergic acid butanolamide
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |